What changed in Jazz Pharmaceuticals plc's latest annual report
In the year ended 31 Dec 2025, Jazz Pharmaceuticals plc's revenue rose 4.9% to USD 4.27bn, from USD 4.07bn; cash and cash equivalents fell 42.3% to USD 1.39bn, from USD 2.41bn; long-term debt fell 28.8% to USD 4.33bn, from USD 6.08bn.
Year ended 31 Dec 2025. Source: 10-K filed 24 Feb 2026, read it on SEC EDGAR.
USD 4.07bn to USD 4.27bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 4.07bn | 4.27bn | Up 4.9% |
| Net income | 560.12m | -356.15m | Not comparable |
| Total assets | 12.01bn | 11.66bn | Down 2.9% |
| Long-term debt | 6.08bn | 4.33bn | Down 28.8% |
| Cash and cash equivalents | 2.41bn | 1.39bn | Down 42.3% |
| Shareholders' equity | 4.09bn | 4.32bn | Up 5.5% |
Questions people ask
Did Jazz Pharmaceuticals plc's revenue grow last year?
Revenue grew 4.9%, from USD 4.07bn to USD 4.27bn in the year ended 31 Dec 2025.
Is Jazz Pharmaceuticals plc profitable?
Not in its latest year: it reported a net loss of USD 356.15m in the year ended 31 Dec 2025. The year before: USD 560.12m.
How much cash and debt does Jazz Pharmaceuticals plc have?
At its latest year end (31 Dec 2025), Jazz Pharmaceuticals plc reported cash and cash equivalents of USD 1.39bn and long-term debt of USD 4.33bn.
Where do these numbers come from?
From Jazz Pharmaceuticals plc's own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Jazz Pharmaceuticals plc?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Pharmaceutical Preparations companies
- Eli Lilly And CompanyCash and cash equivalents up 122.4%
- Johnson & JohnsonNet income up 90.6%
- AbbVie Inc.Revenue up 8.6%
- Merck & Co., Inc.Long-term debt up 35.7%
- Abbott LaboratoriesNet income down 51.3%
- Pfizer IncCash and cash equivalents up 9.5%
- Vertex Pharmaceuticals Inc / MaTotal liabilities up 13.9%
- Bristol-Myers Squibb CompanyShareholders' equity up 13.1%